UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013978
Receipt number R000016158
Scientific Title Lanthanum carbonate impacts on calcification regulating factors in chronic kidney disease
Date of disclosure of the study information 2014/05/31
Last modified on 2019/01/31 18:35:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Lanthanum carbonate impacts on calcification regulating factors in chronic kidney disease

Acronym

MBD-CRF study

Scientific Title

Lanthanum carbonate impacts on calcification regulating factors in chronic kidney disease

Scientific Title:Acronym

MBD-CRF study

Region

Japan


Condition

Condition

Outpatients with chronic kidney disease stage 3-5 in department of medicine, Kidney Center of Tokyo Women's Medical University

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Effect of lanthanum carbonate versus calcium carbonate on calcium regulating factors in chronic kidney disease stage 3-5

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

Comparison of serum Fetuin-A levels between two groups treated with lanthanum carbonate and calcium carbonate

Key secondary outcomes

Serum levels of phosphate, calcium, intact PTH, high sensitive CRP, FGF23, Klotho, calcium protein particle, matrix gla protein, osteoprotegerin, osteopontin, Apo B48, MDA-LDL, and pentraxin 3.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Lanthanum carbonate is administered for 12 weeks. Dose of lanthanum carbonate is 750-2250 mg/day. Lanthanum carbonate is administered 3 times/day.

Interventions/Control_2

Calcium carbonate is administered
for 12 weeks. Dose of calcium carbonate
is 3 g/day. Calcium carbonate is administered 3 times/day.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Over 20 years old when informed concent
2)Chronic Kidney Disease stage 3-5(GFR<60 ml/min/1.73m2)
3)Patients over 3.0 mg/dL of serum phosphate levels and without treatments with phosphate binders
4)Patients who provided written concent to participate in this study after a sufficient explanation.

Key exclusion criteria

1)Patients who have a contraindication that is shown in the product documents of lanthanum carbonate or calcium carbonate.
2)Patients with malignant diseases or the possibility of maignant diseases of entry.
3)Patients with a past history of renal transplantation.
4)Pregnant women or women with possibility of pregnancy.
5)Patients who made a judgmental decision as an inadequate patient by the principal investigator

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kosaku Nitta

Organization

Tokyo Women's Medical University

Division name

Department of Medicine, Kidney Center

Zip code


Address

8-1, Kawada-chou, Shinjuku-ku, Tokyo 162-8666, Japan

TEL

03-3353-8111

Email

knitta@kc.twmu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yukari Asamiya

Organization

Tokyo Women's Medical University

Division name

Department of Medicine, Kidney Center

Zip code


Address

8-1, Kawada-chou, Shinjuku-ku, Tokyo 162-8666, Japan

TEL

03-3353-8111

Homepage URL


Email

strawberry_age_order@yahoo.co.jp


Sponsor or person

Institute

Department of Medicine, Kidney Center, Tokyo Women's Medical University

Institute

Department

Personal name



Funding Source

Organization

Bayer HealthCare

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京女子医科大学病院(東京都)


Other administrative information

Date of disclosure of the study information

2014 Year 05 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 05 Month 31 Day

Date of IRB


Anticipated trial start date

2014 Year 06 Month 01 Day

Last follow-up date

2018 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 05 Month 16 Day

Last modified on

2019 Year 01 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016158


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name